Glucocorticoid pharmacogenetics in pediatric idiopathic nephrotic syndrome

Eva Cuzzoni, Sara De Iudicibus, Raffaella Franca, Gabriele Stocco, Marianna Lucafò, Marco Pelin, Diego Favretto, Andrea Pasini, Giovanni Montini, Giuliana Decorti

Research output: Contribution to journalArticle


Idiopathic nephrotic syndrome represents the most common type of primary glomerular disease in children: glucocorticoids (GCs) are the first-line therapy, even if considerable interindividual differences in thepir efficacy and side effects have been reported. Immunosuppressive and anti-inflammatory effects of these drugs are mainly due to the GC-mediated transcription regulation of pro-and anti-inflammatory genes. This mechanism of action is the result of a complex multistep pathway that involves the glucocorticoid receptor and several other proteins, encoded by polymorphic genes. Aim of this review is to highlight the current knowledge on genetic variants that could affect GC response, particularly focusing on children with idiopathic nephrotic syndrome.

Original languageEnglish
Pages (from-to)1631-1648
Number of pages18
Issue number14
Publication statusPublished - Sep 1 2015



  • glucocorticoid receptor
  • glucocorticoid receptor heterocomplex
  • glucocorticoids
  • idiopathic nephrotic syndrome
  • inflammatory mediators
  • P-gp
  • polymorphisms

ASJC Scopus subject areas

  • Pharmacology
  • Genetics
  • Molecular Medicine

Cite this

Cuzzoni, E., De Iudicibus, S., Franca, R., Stocco, G., Lucafò, M., Pelin, M., Favretto, D., Pasini, A., Montini, G., & Decorti, G. (2015). Glucocorticoid pharmacogenetics in pediatric idiopathic nephrotic syndrome. Pharmacogenomics, 16(14), 1631-1648.